AstraZeneca Seeks US FDA Approval for Lung Cancer Treatment With Tagrisso-Orpathys Combination
AstraZeneca has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for a combination of Tagrisso (osimertinib) and Orpathys (savolitinib) for certain patients with advanced lung cancer.
The application, announced by HUTCHMED on September 29, covers adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours show MET overexpression or amplification and whose disease has progressed on or after treatment with an EGFR-targeted therapy. Orpathys is jointly developed by AstraZeneca and HUTCHMED, while AstraZeneca handles commercialization.
The filing is an important regulatory step, but it is not an FDA approval. The regulator still has to review the application before deciding whether the combination can be marketed for the proposed US indication.
For investors, the development matters because Tagrisso is already one of AstraZeneca's major oncology products, while the filing could expand the commercial opportunity around its established EGFR-focused lung-cancer franchise.
What Treatment Is AstraZeneca Seeking Approval For?
The proposed treatment combines two targeted medicines.
Tagrisso, or osimertinib, is a third-generation irreversible EGFR tyrosine kinase inhibitor (TKI). It is already approved in the US and more than 120 other countries for several EGFR-mutated NSCLC indications. Orpathys, or savolitinib, is an oral, selective MET TKI designed to block the MET signalling pathway.
The proposed US use focuses on a specific problem that can develop after treatment with an EGFR-targeted drug.
EGFR is a protein involved in signals that encourage cells to grow and divide. In some lung cancers, mutations in the EGFR gene can drive tumour growth. Over time, however, tumours can develop additional mechanisms of resistance. One of the more important mechanisms is increased MET activity.
AstraZeneca and HUTCHMED estimate that about 34% of tumours can develop high levels of MET overexpression or amplification after progression on a third-generation EGFR-TKI, according to the companies' development materials.
The combination therefore aims to suppress both pathways rather than continuing with EGFR inhibition alone.
SAFFRON Data Supports the FDA Filing
The US application is supported by results from the SAFFRON Phase III trial, a global study involving 338 patients with EGFR-mutated locally advanced or metastatic NSCLC, MET overexpression or amplification, and disease progression following first- or second-line Tagrisso treatment.
In the trial, patients received either Orpathys plus Tagrisso or doublet platinum-based chemotherapy.
AstraZeneca and HUTCHMED said the combination produced statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy. The safety profile was consistent with the known safety profiles of the medicines, and the companies reported no new safety findings.
PFS measures how long patients live without their cancer worsening, while OS measures how long patients live from the relevant starting point. Both are important endpoints when regulators assess the effectiveness of cancer treatments.
The SAFFRON trial was conducted across 230 centres in 29 countries, giving the filing a broad international clinical dataset.
The results are scheduled to be presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026, according to HUTCHMED.
Why MET Resistance Matters in Lung Cancer
The commercial and medical rationale for the application rests on a familiar challenge in targeted cancer treatment: the disease can adapt.
Tagrisso has become an important therapy for EGFR-mutated lung cancer, including advanced disease. But a successful initial response does not necessarily prevent the cancer from developing new resistance mechanisms.
When MET overexpression or amplification becomes a driver of progression, simply continuing EGFR inhibition may not be sufficient.
The Tagrisso-Orpathys strategy attempts to address that problem with an all-oral, biomarker-directed combination. Biomarker-directed treatment means the medicine is intended for patients selected based on a measurable biological feature of their cancer—in this case, MET abnormalities alongside EGFR-mutated disease.
That could potentially create a more defined treatment pathway for a patient group with limited targeted options after progression on osimertinib.
AstraZeneca Already Has a Large Tagrisso Franchise
The filing also has significance beyond one regulatory application because it builds around one of AstraZeneca's established medicines.
In the first half of 2026, Tagrisso generated $3.775 billion in revenue, up 8% year over year at actual exchange rates and 6% at constant exchange rates, according to AstraZeneca's regulatory filing. The company said demand remained strong across indications and key regions.
AstraZeneca is increasingly using Tagrisso as the backbone of a broader treatment strategy across EGFR-mutated NSCLC.
Recent clinical programmes include combinations with chemotherapy and Orpathys in different disease settings. AstraZeneca has said the goal is to extend Tagrisso's clinical value across stages of disease and different lines of therapy.
For investors, expanding an existing commercial franchise can be strategically attractive because it potentially allows the company to build on an established physician and patient base rather than relying entirely on a new standalone product.
Orpathys Already Has Regulatory Validation in China
The US application also follows regulatory progress in other markets.
The Orpathys-Tagrisso combination was approved in China in June 2025 for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy. That approval was based on the SACHI Phase III trial.
In SACHI, the combination significantly extended progression-free survival compared with platinum-based chemotherapy. HUTCHMED reported investigator-assessed median PFS of 8.2 months versus 4.5 months, with a hazard ratio of 0.34 in the intention-to-treat population at the interim analysis.
The global SAFFRON trial was designed to provide evidence in a broader international setting and is now supporting the US submission.
The combination has also received a temporary authorization in Switzerland for a related post-Tagrisso population with high MET overexpression or amplification.
What the FDA Decision Could Mean for AstraZeneca and HUTCHMED
The immediate financial impact of the filing should not be overstated.
Submitting an NDA does not generate the same commercial effect as receiving a marketing approval. The FDA review must still be completed, and the eventual label could determine which patients are eligible, how the medicine can be used and the size of the addressable market.
For AstraZeneca, however, a successful approval could provide another way to extend Tagrisso's commercial life in EGFR-mutated lung cancer.
The potential benefit to HUTCHMED is also notable because Orpathys is one of the company's key globally partnered assets. AstraZeneca is responsible for commercialization, giving HUTCHMED a route to international commercialization through a major pharmaceutical partner.
The companies have already demonstrated the model in China, where the combination received approval and AstraZeneca markets the products.
Investors Should Also Watch the Competitive Landscape
The lung-cancer market is highly competitive, and a strong clinical result does not automatically translate into commercial leadership.
Patients whose EGFR-mutated cancer progresses on Tagrisso can have different resistance mechanisms, meaning treatment selection may depend on the specific biological characteristics of each tumour.
That makes biomarker testing increasingly important. AstraZeneca has highlighted the role of MET testing because the proposed combination is designed specifically for patients whose cancers develop MET-driven resistance.
Competition from other targeted combinations and emerging therapies is another consideration. The broader NSCLC treatment landscape continues to evolve as pharmaceutical companies investigate antibody-drug conjugates, targeted therapies and combinations designed to delay or overcome resistance.
The ability to demonstrate durable patient benefit, maintain a manageable safety profile and fit into clinical practice will therefore be crucial after any potential approval.
What Investors Should Watch Next
The next major catalyst is the FDA review itself.
Investors should watch for the FDA's acceptance and review timeline, any requests for additional information, the eventual regulatory decision and the precise commercial label if approval is granted.
The ESMO 2026 presentation of SAFFRON's data will also be important because fuller clinical results should provide more detail beyond the initial high-level announcement.
For AstraZeneca, investors can also track Tagrisso revenue growth and the company's ability to expand the medicine into new treatment settings. H1 2026 results already showed Tagrisso continuing to generate billions of dollars in quarterly sales globally.
For HUTCHMED, the progress of Orpathys beyond China remains particularly relevant because the US filing represents another potential step toward international commercialization.
Bottom Line
AstraZeneca has filed with the US FDA for approval of Tagrisso plus Orpathys for a specific group of patients with advanced EGFR-mutated lung cancer whose tumours have MET overexpression or amplification and whose disease has progressed after EGFR-targeted therapy.
The filing is supported by positive Phase III SAFFRON results showing statistically significant improvements in both progression-free and overall survival versus platinum-based chemotherapy. The combination is already approved in China for a related indication, giving the programme regulatory experience outside the US.
For investors, the key issue now is execution: how the FDA reviews the application, what label it ultimately grants and whether AstraZeneca and HUTCHMED can turn the clinical evidence into a meaningful expansion of the lung-cancer franchise.
Follow AIViralHub for more pharmaceutical news, FDA developments, biotech stocks and global healthcare business updates.
This article is for informational and educational purposes only and should not be considered investment advice.